Status of vaccine research and development of vaccines for tuberculosis
Evans TG, Schrager L, Thole J.
Vaccine. June 2016
Vaccination against tuberculosis with whole cell mycobacterial vaccines
Scriba TJ, Kaufmann SHE, Lambert PH, Sanicas M, Martin C, Neyrolles O.
The Journal of Infectious Disease May 2016
Mycobacterium tuberculosis infection and vaccine development
Tang J, Yam WC, Chen Z.
Tuberculosis May 2016
Tuberculosis vaccines and prevention of infection
Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.
Microbiol Mol Biol Rev. Dec 2014
Side-by-side comparison of T cell reactivity to Mycobacterium tuberculosis antigens in diverse populations
Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, et al.
Tuberculosis (Edinb). 2015 Aug
Tuberculosis vaccines: Time for a global strategy
Stefan H. E. Kaufmann, Thomas G. Evans, Willem A. Hanekom
Science Translational Medicine 25 Feb 2015
Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool
Christopher L. Karp, Christopher B. Wilson, Lynda M. Stuart
Immunological Reviews 2015
Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
Tom H. M. Ottenhoff, Stefan H. E. Kaufmann
PLoS Pathogens 2012
Tuberculosis vaccines: beyond Bacille Calmette –Guerin
Phil Trans R Soc 2011
Learning About Protective Immunity
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
Birahim Pierre Ndiaye, Friedrich Thienemann, Martin Ota, et al. FWACP for the MVA85A 030 trial investigators
The Lancet Respiratory Medicine 2015
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C
Lancet Respiratory Med. Dec 2015
- Identification of antigens presented by MHC for vaccines against tuberculosis
Bettencourt P, Müller J, Nicastri A, Cantillon D, Madhavan M, Charles PD, Fotso CB, Wittenberg R, Bull N, Pinpathomrat N, Waddell SJ, Stylianou E, Hill AVS, Ternette N, McShane H.
NPJ Vaccines. January 2020
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Alexander G. White, Pauline Maiello, M. Teresa Coleman, Jaime A. Tomko, L. James Frye, Charles A. Scanga, Philana Ling Lin, JoAnne L. Flynn
Journal of Visualized Experiments
- Drug-resistant TB: deadly, costly and in need of a vaccine
Manjelievskaia J, Erck D, Piracha S, Schrager L
Trans Royal Society of Trop Med and Hygiene March 2016
M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens
Coscolla M, Copin R, Sutherland J, Gehre F, de Jong B, Owolabi O, Mbayo G, Giardina F, Ernst, JD, Gagneux S.
Cell Host and Microbe 2015
TB vaccines; promoting rapid and durable protection in the lung.
Andersen P, Urdahl KB.
Curr Opin Immunol Jun 2015
The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis.
Henao-Tamayo M, Shanley CA, Verma D, Zilavy A, Stapleton MC, Furney SK, Podell B, Orme IM.
PLoS ONE Sept 2015
Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects
Helen Winter, Erica Egizi, Stephen Murray, et al.
Antimicrob Agents Chemother 2015
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
Lei Gao, Wei Lu, Liqiong Bai, et al. for the LATENTTB-NSTM study team
The Lancet Infectious Diseases 2015